Paris:  EUROAPI aims to reinvent active pharmaceutical ingredients in order to sustainably meet the demand of patients and customers, globally. With approximately 200 products in their portfolio, EUROAPI is a major player in the active pharmaceutical ingredients industry. They also develop novel molecules through their Contract Development and Manufacturing Organization (CDMO) activities and offer a wide range of technologies. Their 3,450 members are inspired to take action for health by facilitating access to essential therapies. EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries with strong research and development capabilities and six manufacturing sites in Europe.

Health sovereignty issues are being further addressed by EUROAPI in Europe and France. The Group has announced numerous initiatives to boost its production capacities for a number of active pharmaceutical ingredients that the French government has designated as essential medicines. On its Vertolaye (Puy-de-Dôme) site, EUROAPI's Francopia controlled substances subsidiary will invest in R&D activities. By 2027, the goal of these R&D efforts is to boost EUROAPI's production of morphine, its derivatives, and their antagonists, which are used as antidotes.

The Group wants to come up with a novel method for the plant extraction stage that could help build strategic stocks by reducing industrial cycle times and increasing productivity by over 30 percent. In addition, this novel method would reduce energy consumption and enhance solvent recycling. EUROAPI intends to make investments in more adaptable technologies and equipment during the chemical synthesis phase, increasing production capacity by 15 to 20%.

EUROAPI aspire to make additional investments to expand its production capacity following the successful completion of the R&D projects. From 2026, approximately 15% of total investments in R&D and 85% in capital expenditures could reach USD 76.5 million. Through France 2030 investment plan, the French government plans to help partially in these investments. Furthermore, EUROAPI has presented innovative projects to help cover the need for crucial medicines like macrolide antibiotics and corticosteroids that are currently imported, by 2030 as part of the Important Project of Common European Interest (IPCEI) that is presently being evaluated by the European Commission.

EUROAPI also aims to develop cutting-edge processes and technologies at the Vertolaye site for corticosteroids, including methylprednisolone, which are used for their anti-inflammatory and immunosuppressive properties. The project to relaunch production would be implemented at the Saint-Aubin-lès-Elbeuf (Seine-Maritime) site, allowing EUROAPI to expand its product portfolio in the global market for the macrolide antibiotics that are used to treat infectious diseases.

Mr. Roland Lescure, Minister Delegate In-Charge of Industry said, “EUROAPI projects are emblematic of what we are striving for when it comes to health sovereignty: increase our production capacity or relocate medicines that are essential for the health of the French people, building on the development of innovative production processes that are more competitive and environmentally friendly. These projects are part of the eight new relocation projects announced today in Ardèche by the President of the Republic, which will allow us to significantly reduce our dependence on non-European imports on a number of drugs over the next five years.”

Karl Rotthier, Chief Executive Officer of EUROAPI said, “EUROAPI is proud to address health sovereignty challenges identified by the French Government and to fight drug shortages. Innovation will enable us to increase our production in order to ensure the sustainable, competitive and integrated manufacturing of pharmaceutical intermediates and active ingredients in Europe, such as anti-inflammatory drugs and antibiotics, all essential to public health.”

According to TechSci Research, EUROAPI supporting the production of several vital APIs listed by French government may lead to an increase in domestic pharmaceutical production to help Europe and France. This can encourage the growth of the pharmaceutical market in Europe by expanding production capacities and by attracting investments. Increased production can also contribute to the export potential of the pharmaceutical sector, boosting the overall economy. EUROAPI can help to strengthen local supply chains by encouraging API’s production, this can amplify the resilience and reliability of pharmaceutical market by ensuring a consistent availability of medicines to meet the healthcare needs of the population. A vigorous supply chain can attract more investments. Increased production of APIs can also decrease the reliance on foreign suppliers for import of essential medicines. The reduced dependency can result in a more stable pharmaceutical market in Europe. EUROAPI’s initiative can create opportunities for innovation and research within the pharmaceutical market. Supporting the supply of vital medicines may incorporate collaboration with local pharmaceutical companies, academia, and research institutions. These collaborations may offer the advancements in pharmaceutical technologies, development of new drugs, and improvement of existing medicines. Increased innovation and research activities can drive the growth of pharmaceutical market by introducing novel products and expanding therapeutic options in the region.